Nektar Therapeutics
NKTR
343 hedge funds and large institutions have $5.41B invested in Nektar Therapeutics in 2018 Q4 according to their latest regulatory filings, with 50 funds opening new positions, 138 increasing their positions, 122 reducing their positions, and 92 closing their positions.
78% more call options, than puts
Call options by funds: $89.9M | Put options by funds: $50.5M
13% more repeat investments, than reductions
Existing positions increased: 138 | Existing positions reduced: 122
0.18% more ownership
Funds ownership: 6.17% → 6.36% (+0.18%)
12% less funds holding
Funds holding: 389 → 343 (-46)
44% less capital invested
Capital invested by funds: $9.73B → $5.41B (-$4.32B)
46% less first-time investments, than exits
New positions opened: 50 | Existing positions closed: 92
50% less funds holding in top 10
Funds holding in top 10: 6 → 3 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OppenheimerFunds
New York
|
+$213M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$122M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$82.2M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$29.4M |
| 5 |
D.E. Shaw & Co
New York
|
+$25.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$80.8M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$67.8M |
| 3 |
Millennium Management
New York
|
-$51.7M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$33.1M |
| 5 |
Primecap Management
Pasadena,
California
|
-$30.4M |
NKTR Hedge Fund Activity: Q4 2018 in Review
343 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q4 2018, worth a combined $5.41B — down 44% from $9.73B a quarter earlier.
Sellers outnumbered buyers: 92 funds closed out of NKTR and 50 opened new positions — a net loss of 42 holders — while 122 trimmed existing stakes and 138 added.
The largest buyer was OppenheimerFunds, adding an estimated $213M. The largest seller was Janus Henderson Group, cutting an estimated $80.8M.
- 343 institutional investors held Nektar Therapeutics (NKTR) as of Q4 2018, down from 389 in Q3 2018.
- Funds reported $5.41B of Nektar Therapeutics stock for Q4 2018, down 44% quarter-over-quarter.
- 50 funds opened new Nektar Therapeutics positions in Q4 2018 and 92 closed out, a net change of -42 holders.
- The largest Nektar Therapeutics buyer in Q4 2018 was OppenheimerFunds, an estimated $213M added.
- The largest Nektar Therapeutics seller in Q4 2018 was Janus Henderson Group, an estimated $80.8M sold.
Based on aggregated 13F filings for Q4 2018.